Antidepressants and panic disorder

Clinical Neuropsychiatry

Volumn 9, Issue 2, 2012, Pages 84-101

  Andrisano, Costanza ^a   Balzarro, Beatrice ^a   Fabbri, Chiara ^a   Chiesa, Alberto ^a,b   Serretti, Alessandro ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

Anxiety; Panic disorder; SSRIs; Venlafaxine

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MAPROTILINE; MILNACIPRAN; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; PHENELZINE; PLACEBO; REBOXETINE; RITANSERIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE;

AGITATION; ANOREXIA; ANTICHOLINERGIC SYNDROME; ANXIETY DISORDER; APATHY; ARTICLE; ASTHENIA; AUTONOMIC NEUROPATHY; BINDING AFFINITY; BLURRED VISION; COGNITIVE DEFECT; COGNITIVE THERAPY; COMPARATIVE EFFECTIVENESS; CONCENTRATION LOSS; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DISTRESS SYNDROME; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL SYMPTOM; HEART PALPITATION; HUMAN; HYPERPROLACTINEMIA; INCREASED APPETITE; INSOMNIA; IRRITABILITY; LOW DRUG DOSE; MEMORY DISORDER; MOOD DISORDER; MYALGIA; NAUSEA; NEUROTRANSMITTER RELEASE; ORTHOSTATIC HYPOTENSION; PANIC; PARKINSONISM; PATHOGENESIS; PATIENT EDUCATION; PATIENT PREFERENCE; PHOBIA; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOCIAL AVOIDANCE BEHAVIOR; SOMNOLENCE; SWEATING; TACHYCARDIA; TREATMENT DURATION; TREATMENT PLANNING; TREMOR; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; WITHDRAWAL SYNDROME; XEROSTOMIA;

EID: 84863993352     PISSN: 17244935     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (241)

1. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th Edition.
2. American Psychiatric Association, Washington DC. American Psychiatric Association (2009). Treatment of patients with panic disorder, second edition. http://www.psychiatryonline.com/pracGuide/pracGuideTopic_9.aspx.
3. Amore M, Magnani K, Cerisoli M, Casagrande C, Ferrari G (1999a). Panic Disorder. A long-term treatment study: fluoxetine vs imipramine. Human Psychopharmacology 14, 429-434.
4. Amore M, Magnani K, Cerisoli M, Ferrari G (1999b). Shortterm and long-term evaluation of selective serotonine reuptake inhibitors in the treatment of panic disorder: fluoxetine vs citalopram. Hum Psychopharmacol 435-440.
5. Andersch S, Rosenberg NK, Kullingsjo H, Ottosson JO, Bech P, Bruun-Hansen J, Hanson L, Lorentzen K, Mellergard M, Rasmussen S, et al. (1991). Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder. A Scandinavian multicenter study. Acta Psychiatr Scand Suppl 365, 18-27.
6. Argyle N, Deltito J, Allerup P, Maier W, Albus M, Nutzinger D, Rasmussen S, Ayuso JL, Bech P (1991). The Panic-Associated Symptom Scale: measuring the severity of panic disorder. Acta Psychiatr Scand 83, 20-6.
7. Asnis GM, Hameedi FA, Goddard AW, Potkin SG, Black D, Jameel M, Desagani K, Woods SW (2001). Fluvoxamine in the treatment of panic disorder: a multi-center, doubleblind, placebo-controlled study in outpatients. Psychiatry Res 103, 1-14.
8. Baetz M, Bowen RC (1998). Efficacy of divalproex sodium in patients with panic disorder and mood instability who have not responded to conventional therapy. Can J Psychiatry 43, 73-7.
9. Bailey JE, Papadopoulos A, Seddon K, Nutt DJ (2009). A comparison of the effects of a subtype selective and nonselective benzodiazepine receptor agonist in two CO(2) models of experimental human anxiety. J Psychopharmacol 23, 117-22.
10. Bakker A, van Balkom AJ, Stein DJ (2005). Evidence-based pharmacotherapy of panic disorder. Int J Neuropsychopharmacol 8, 473-82.
11. Ballenger JC (1993). Panic disorder: efficacy of current treatments. Psychopharmacol Bull 29, 477-86.
12. Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Baldwin DS, den Boer JA, Kasper S, Shear MK (1998a). Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 59 Suppl 8, 47-54.
13. Ballenger JC, Wheadon DE, Steiner M, Bushnell W, Gergel IP (1998b). Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 155, 36-42.
14. Bandelow B, Behnke K, Lenoir S, Hendriks GJ, Alkin T, Goebel C, Clary CM (2004). Sertraline versus paroxetine in the treatment of panic disorder: an acute, double-blind noninferiority comparison. J Clin Psychiatry 65, 405-13.
15. Bandelow B, Ruther E (2004). Treatment-resistant panic disorder. CNS Spectr 9, 725-39.
16. Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ, Zohar J, Hollander E, Kasper S, Moller HJ, Bandelow B, Allgulander C, Ayuso-Gutierrez J, Baldwin DS, Buenvicius R, Cassano G, Fineberg N, Gabriels L, Hindmarch I, Kaiya H, Klein DF, Lader M, Lecrubier Y, Lepine JP, Liebowitz MR, Lopez-Ibor JJ, Marazziti D, Miguel EC, Oh KS, Preter M, Rupprecht R, Sato M, Starcevic V, Stein DJ, van Ameringen M, Vega J (2008). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry 9, 248-312.
17. Bang LM, Keating GM (2004). Paroxetine controlled release. CNS Drugs 18, 355-64; discussion 365-6.
18. Barsky AJ, Delamater BA, Orav JE (1999). Panic disorder patients and their medical care. Psychosomatics 40, 50-6.
19. Baumann P (1996). Pharmacology and pharmacokinetics of citalopram and other SSRIs. Int Clin Psychopharmacol 11 Suppl 1, 5-11.
20. Benjamin S, Doraiswamy PM (2011). Review of the use of mirtazapine in the treatment of depression. Expert Opin Pharmacother 12, 1623-32.
21. Berger P, Sachs G, Amering M, Holzinger A, Bankier B, Katschnig H (2004). Personality disorder and social anxiety predict delayed response in drug and behavioral treatment of panic disorder. J Affect Disord 80, 75-8.
22. Bertani A, Perna G, Migliarese G, Di Pasquale D, Cucchi M, Caldirola D, Bellodi L (2004). Comparison of the treatment with paroxetine and reboxetine in panic disorder: a randomized, single-blind study. Pharmacopsychiatry 37, 206-10.
23. Black DW, Wesner R, Bowers W, Gabel J (1993). A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Arch Gen Psychiatry 50, 44-50.
24. Blaya C, Seganfredo AC, Dornelles M, Torres M, Paludo A, Heldt E, Manfro GG (2007). The efficacy of milnacipran in panic disorder: an open trial. Int Clin Psychopharmacol 22, 153-8.
25. Bolden-Watson C, Richelson E (1993). Blockade by newlydeveloped antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 52, 1023-9.
26. Boyer EW, Shannon M (2005). The serotonin syndrome. N Engl J Med 352, 1112-20.
27. Bradwejn J, Ahokas A, Stein DJ, Salinas E, Emilien G, Whitaker T (2005). Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study. Br J Psychiatry 187, 352-9.
28. Brunello N, Racagni G (1998). Rationale for the development of noradrenaline reuptake inhibitors. Human Psychopharmacology 13, 13-19.
29. Bystritsky A, Kerwin L, Niv N, Natoli JL, Abrahami N, Klap R, Wells K, Young AS (2010). Clinical and subthreshold panic disorder. Depress Anxiety 27, 381-9.
30. Carli V, Sarchiapone M, Camardese G, Romano L, DeRisio S (2002). Mirtazapine in the treatment of panic disorder. Arch Gen Psychiatry 59, 661-2.
31. Carpenter LL, Leon Z, Yasmin S, Price LH (1999). Clinical experience with mirtazapine in the treatment of panic disorder. Ann Clin Psychiatry 11, 81-6.
32. Carrera M, Herran A, Ramirez ML, Ayestaran A, Sierra-Biddle D, Hoyuela F, Rodriguez-Cabo B, Vazquez-Barquero JL (2006). Personality traits in early phases of panic disorder: implications on the presence of agoraphobia, clinical severity and short-term outcome. Acta Psychiatr Scand 114, 417-25.
33. Cia H, Brizuela J, Cascardo E, Varela M (2006). Clonazepam and milnacipran in the treatment of patients with panic disorder and comorbid depression. Primary Care and Community Psychiatry 11, 51-56.
34. Clayton A, Kornstein S, Prakash A, Mallinckrodt C, Wohlreich M (2007). Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder. J Sex Med 4, 917-29.
35. Cloos JM (2005). The treatment of panic disorder. Curr Opin Psychiatry 18, 45-50.
36. Coplan JD, Lydiard RB (1998). Brain circuits in panic disorder. Biol Psychiatry 44, 1264-76.
37. Coplan JD, Pine DS, Papp LA (1996). An algorithm-oriented treatment approach for panic disorder. Psychiatric Annals 264, 192-201.
38. Dannon PN, Iancu I, Cohen A, Lowengrub K, Grunhaus L, Kotler M (2004). Three year naturalistic outcome study of panic disorder patients treated with paroxetine. BMC Psychiatry 4, 16.
39. Dannon PN, Iancu I, Grunhaus L (2002). The efficacy of reboxetine in the treatment-refractory patients with panic disorder: an open label study. Hum Psychopharmacol 17, 329-33.
40. Dannon PN, Iancu I, Lowengrub K, Gonopolsky Y, Musin E, Grunhaus L, Kotler M (2007). A naturalistic long-term comparison study of selective serotonin reuptake inhibitors in the treatment of panic disorder. Clin Neuropharmacol 30, 326-34.
41. Dannon PN, Iancu I, Lowengrub K, Grunhaus L, Kotler M (2006). Recurrence of panic disorder during pregnancy: a 7-year naturalistic follow-up study. Clin Neuropharmacol 29, 132-7.
42. de Boer T (1995). The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol 10 Suppl 4, 19-23.
43. de Boer T (1996). The pharmacologic profile of mirtazapine. J Clin Psychiatry 57 Suppl 4, 19-25.
44. De Montigny C, Haddjeri N, Mongeau R, Blier P (1995). The effects of mirtazapine on the interactions between central noradrenergic and serotoninergic systems. CNS Drugs 4, 13-17.
45. Deakin B, Dursun S (2002). Optimizing antidepressant treatment: efficacy and tolerability. Int Clin Psychopharmacol 17 Suppl 1, S13-24.
46. Delgado PL, Brannan SK, Mallinckrodt CH, Tran PV, McNamara RK, Wang F, Watkin JG, Detke MJ (2005). Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder. J Clin Psychiatry 66, 686-92.
47. Dell'Osso B, Buoli M, Baldwin DS, Altamura AC (2010). Serotonin norepinephrine reuptake inhibitors (SNRIs) in anxiety disorders: a comprehensive review of their clinical efficacy. Hum Psychopharmacol 25, 17-29.
48. Den Boer JA, Westenberg HG (1988). Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a doubleblind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol 3, 59-74.
49. Den Boer JA, Westenberg HG (1990). Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin. Psychopharmacology (Berl) 102, 85-94.
50. Eaton WW, Kessler RC, Wittchen HU, Magee WJ (1994). Panic and panic disorder in the United States. Am J Psychiatry 151, 413-20.
51. Eisenthal S, Emery R, Lazare A, Udin H (1979). "Adherence" and the negotiated approach to patienthood. Arch Gen Psychiatry 36, 393-8.
52. El Mansari M, Sanchez C, Chouvet G, Renaud B, Haddjeri N (2005). Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: an in vivo electrophysiological study in rat brain. Neuropsychopharmacology 30, 1269-77.
53. Fahy TJ, O'Rourke D, Brophy J, Schazmann W, Sciascia S (1992). The Galway Study of Panic Disorder. I: Clomipramine and lofepramine in DSM III-R panic disorder: a placebo controlled trial. J Affect Disord 25, 63-75.
54. Fava M, Rosenbaum JF, Hoog SL, Tepner RG, Kopp JB, Nilsson ME (2000). Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression. J Affect Disord 59, 119-26.
55. Fawcett J, Barkin RL (1998). Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J Affect Disord 51, 267-85.
56. Feighner JP (1995). Cardiovascular safety in depressed patients: focus on venlafaxine. J Clin Psychiatry 56, 574-9.
57. Feighner JP (1999). Mechanism of action of antidepressant medications. J Clin Psychiatry 60 Suppl 4, 4-11; discussion 12-3.
58. Ferguson JM, Khan A, Mangano R, Entsuah R, Tzanis E (2007). Relapse prevention of panic disorder in adult outpatient responders to treatment with venlafaxine extended release. J Clin Psychiatry 68, 58-68.
59. Ferris RM, Beaman OJ (1983). Bupropion: a new antidepressant drug, the mechanism of action of which is not associated with down-regulation of postsynaptic beta-adrenergic, serotonergic (5-HT2), alpha 2-adrenergic, imipramine and dopaminergic receptors in brain. Neuropharmacology 22, 1257-67.
60. Ferris RM, Maxwell RA, Cooper BR, Soroko FE (1982). Neurochemical and neuropharmacological investigations into the mechanisms of action of bupropion. HCl-a new atypical antidepressant agent. Adv Biochem Psychopharmacol 31, 277-86.
61. Figgitt DP, McClellan KJ (2000). Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders. Drugs 60, 925-54.
62. Freire RC, Hallak JE, Crippa JA, Nardi AE (2011). New treatment options for panic disorder: clinical trials from 2000 to 2010. Expert Opin Pharmacother 12, 1419-28.
63. Fryer JD, Lukas RJ (1999). Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther 288, 88-92.
64. Furukawa T, Watanabe N, Churchill R (2007). Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia. Cochrane Database Syst Rev, CD004364.
65. Garakani A, Mathew SJ, Charney DS (2006). Neurobiology of anxiety disorders and implications for treatment. Mt Sinai J Med 73, 941-9.
66. Gillman PK (2005). Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth 95, 434-41.
67. Goddard AW, Brouette T, Almai A, Jetty P, Woods SW, Charney D (2001). Early coadministration of clonazepam with sertraline for panic disorder. Arch Gen Psychiatry 58, 681-6.
68. Goisman RM, Goldenberg I, Vasile RG, Keller MB (1995). Comorbidity of anxiety disorders in a multicenter anxiety study. Compr Psychiatry 36, 303-11.
69. Goodwin RD, Faravelli C, Rosi S, Cosci F, Truglia E, de Graaf R, Wittchen HU (2005). The epidemiology of panic disorder and agoraphobia in Europe. Eur Neuropsychopharmacol 15, 435-43.
70. Goodwin RD, Hoven CW (2002). Bipolar-panic comorbidity in the general population: prevalence and associated morbidity. J Affect Disord 70, 27-33.
71. Gorman JM, Kent JM, Sullivan GM, Coplan JD (2000). Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry 157, 493-505.
72. Guelfi JD, Ansseau M, Corruble E, Samuelian JC, Tonelli I, Tournoux A, Pletan Y (1998). A double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed inpatients. Int Clin Psychopharmacol 13, 121-8.
73. Guy W (1976): Clinical Global Impression: Assesment manual for psychopharmacology. pp 217-222. Washington DC: U.S., Department of Health Education and Welfare.
74. Hindmarch I, Kimber S, Cockle SM (2000). Abrupt and brief discontinuation of antidepressant treatment: effects on cognitive function and psychomotor performance. Int Clin Psychopharmacol 15, 305-18.
75. Hirschmann S, Dannon PN, Iancu I, Dolberg OT, Zohar J, Grunhaus L (2000). Pindolol augmentation in patients with treatment-resistant panic disorder: A double-blind, placebocontrolled trial. J Clin Psychopharmacol 20, 556-9.
76. Hoehn-Saric R, Fawcett J, Munjack DJ, Roy-Byrne PP (1994). A multicentre, double-blind, placebo controlled study of fluvoxamine in the treatment of panic disorder. Neuropsychopharmacology 10 Suppl. 3, P-58-33.
77. Hoehn-Saric R, McLeod DR, Hipsley PA (1993). Effect of fluvoxamine on panic disorder. J Clin Psychopharmacol 13, 321-6.
78. Hollifield M, Thompson PM, Ruiz JE, Uhlenhuth EH (2005). Potential effectiveness and safety of olanzapine in refractory panic disorder. Depress Anxiety 21, 33-40.
79. Hyttel J (1994). Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 9 Suppl 1, 19-26.
80. Ilies-Alexandru D, Zaharia C (2002). Clinical considerations on mirtazapine treatment in depression-panic disorder comorbidity. European Neuropsychopharmacology 12, 42.
81. Ipser JC, Carey P, Dhansay Y, Fakier N, Seedat S, Stein DJ (2006). Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders. Cochrane Database Syst Rev, CD005473.
82. Johnson MR, Lydiard RB, Ballenger JC (1995). Panic disorder. Pathophysiology and drug treatment. Drugs 49, 328-44.
83. Kasper S, Resinger E (2001). Panic disorder: the place of benzodiazepines and selective serotonin reuptake inhibitors. Eur Neuropsychopharmacol 11, 307-21.
84. Katon WJ (2006). Clinical practice. Panic disorder. N Engl J Med 354, 2360-7.
85. Keck PE, Jr., Strawn JR, McElroy SL (2006). Pharmacologic treatment considerations in co-occurring bipolar and anxiety disorders. J Clin Psychiatry 67 Suppl 1, 8-15.
86. Keller MB, Yonkers KA, Warshaw MG, Pratt LA, Gollan JK, Massion AO, White K, Swartz AR, Reich J, Lavori PW (1994). Remission and relapse in subjects with panic disorder and panic with agoraphobia: a prospective shortinterval naturalistic follow-up. J Nerv Ment Dis 182, 290-6.
87. Kent JM (2000). SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet 355, 911-8.
88. Kessler RC, Chiu WT, Jin R, Ruscio AM, Shear K, Walters EE (2006). The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Arch Gen Psychiatry 63, 415-24.
89. Kinzl JF (2009). Major depressive disorder, antidepressants and sexual dysfunction. Neuropsychiatr 23, 134-8.
90. Kipper L, Blaya C, Wachleski C, Dornelles M, Salum GA, Heldt E, Manfro GG (2007). Trauma and defense style as response predictors of pharmacological treatment in panic patients.
91. Knowles J, Weissman M (1995): Panic disorder and agoraphobia. In Oldham J, Riba M (eds) in American Psychiatric Press Review of Psychiatry, vol. 14. pp 383-404 Washington DC, American Psychiatric Press.
92. Koe BK (1990). Preclinical pharmacology of sertraline: a potent and specific inhibitor of serotonin reuptake. J Clin Psychiatry 51 Suppl B, 13-7.
93. Konnopka A, Leichsenring F, Leibing E, Konig HH (2009). Cost-of-illness studies and cost-effectiveness analyses in anxiety disorders: a systematic review. J Affect Disord 114, 14-31.
94. Kruger MB, Dahl AA (1999). The efficacy and safety of moclobemide compared to clomipramine in the treatment of panic disorder. Eur Arch Psychiatry Clin Neurosci 249 Suppl 1, S19-24.
95. Lai CH, Hsu YY (2011). A subtle grey-matter increase in firstepisode, drug-naive major depressive disorder with panic disorder after 6 weeks' duloxetine therapy. Int J Neuropsychopharmacol 14, 225-35.
96. Lai CH, Wu YT (2011). Duloxetine's modest short-term influences in subcortical structures of first episode drugnaive patients with major depressive disorder and panic disorder. Psychiatry Res 194, 157-62.
97. Lamb MHaHM (2000). Fluoxetine: a review of its use in anxiety disorders and mixed anxiety and depression. CSN Drugs 14, 51-80.
98. Learned-Coughlin SM, Bergstrom M, Savitcheva I, Ascher J, Schmith VD, Langstrom B (2003). In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol Psychiatry 54, 800-5.
99. Lecrubier Y, Bakker A, Dunbar G, Judge R (1997). A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand 95, 145-52.
100. Lecrubier Y, Judge R (1997). Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand 95, 153-60.
101. Leinonen E, Lepola U, Koponen H, Turtonen J, Wade A, Lehto H (2000). Citalopram controls phobic symptoms in patients with panic disorder: randomized controlled trial. J Psychiatry Neurosci 25, 24-32.
102. Leonard BE (1992). Pharmacological differences of serotonin reuptake inhibitors and possible clinical relevance. Drugs 43 Suppl 2, 3-9; discussion 9-10.
103. Lepola U, Arato M, Zhu Y, Austin C (2003). Sertraline versus imipramine treatment of comorbid panic disorder and major depressive disorder. J Clin Psychiatry 64, 654-62.
104. Lepola U, Koponen H, Leinonen E (1996). A naturalistic 6-year follow-up study of patients with panic disorder. Acta Psychiatr Scand 93, 181-3.
105. Lepola UM, Wade AG, Leinonen EV, Koponen HJ, Frazer J, Sjodin I, Penttinen JT, Pedersen T, Lehto HJ (1998). A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. J Clin Psychiatry 59, 528-34.
106. Lum FR, Elie R, Ontiveros A (1990). Divalproex sodium's antipanic effect in panic disorder: a placebo-controlled study. Biol Psychiatry 41A-179A.
107. Maier W, Buller R, Philipp M, Heuser I (1988). The Hamilton Anxiety Scale: reliability, validity and sensitivity to change in anxiety and depressive disorders. Journal of Affective Disorders 14, 61-8.
108. Malhotra AK, Murphy GM, Jr., Kennedy JL (2004). Pharmacogenetics of psychotropic drug response. Am J Psychiatry 161, 780-96.
109. Marchesi C (2008). Pharmacological management of panic disorder. Neuropsychiatr Dis Treat 4, 93-106.
110. Marchesi C, Cantoni A, Fonto S, Giannelli MR, Maggini C (2005). The effect of pharmacotherapy on personality disorders in panic disorder: a one year naturalistic study. J Affect Disord 89, 189-94.
111. Marchesi C, Cantoni A, Fonto S, Giannelli MR, Maggini C (2006a). The effect of temperament and character on response to selective serotonin reuptake inhibitors in panic disorder. Acta Psychiatr Scand 114, 203-10.
112. Marchesi C, Cantoni A, Fonto S, Giannelli MR, Maggini C (2006b). Predictors of symptom resolution in panic disorder after one year of pharmacological treatment: a naturalistic study. Pharmacopsychiatry 39, 60-5.
113. Marchesi C, De Panfilis C, Cantoni A, Fonto S, Giannelli MR, Maggini C (2006c). Personality disorders and response to medication treatment in panic disorder: a 1-year naturalistic study. Prog Neuropsychopharmacol Biol Psychiatry 30, 1240-5.
114. Maron E, Shlik J (2006). Serotonin function in panic disorder: important, but why? Neuropsychopharmacology 31, 1-11.
115. Martin EI, Ressler KJ, Binder E, Nemeroff CB (2009). The neurobiology of anxiety disorders: brain imaging, genetics, and psychoneuroendocrinology. Psychiatr Clin North Am 32, 549-75.
116. Massion AO, Dyck IR, Shea MT, Phillips KA, Warshaw MG, Keller MB (2002). Personality disorders and time to remission in generalized anxiety disorder, social phobia, and panic disorder. Arch Gen Psychiatry 59, 434-40.
117. Mattick RP, Andrews G, Hadzi-Pavlovic D, Christensen H (1990). Treatment of panic and agoraphobia. An integrative review. J Nerv Ment Dis 178, 567-76.
118. Mavissakalian MR (2003). Imipramine vs. sertraline in panic disorder: 24-week treatment completers. Ann Clin Psychiatry 15, 171-80.
119. Mavissakalian MR, Perel JM (1989). Imipramine dose-response relationship in panic disorder with agoraphobia. Preliminary findings. Arch Gen Psychiatry 46, 127-31.
120. Mavissakalian MR, Perel JM (1995). Imipramine treatment of panic disorder with agoraphobia: dose ranging and plasma level-response relationships. Am J Psychiatry 152, 673-82.
121. Mavissakalian MR, Perel JM (1999). Long-term maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. Arch Gen Psychiatry 56, 821-7.
122. Mavissakalian MR, Perel JM (2002). Duration of imipramine therapy and relapse in panic disorder with agoraphobia. J Clin Psychopharmacol 22, 294-9.
123. McKenzie LJ, Risch SC (1995). Fibrocystic breast disease following treatment with selective serotonin reuptake inhibitors. Am J Psychiatry 152, 471.
124. McTavish D, Benfield P (1990). Clomipramine. An overview of its pharmacological properties and a review of its therapeutic use in obsessive compulsive disorder and panic disorder. Drugs 39, 136-53.
125. Michelson D, Allgulander C, Dantendorfer K, Knezevic A, Maierhofer D, Micev V, Paunovic VR, Timotijevic I, Sarkar N, Skoglund L, Pemberton SC (2001). Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: randomised, placebo-controlled trial. Br J Psychiatry 179, 514-8.
126. Michelson D, Fava M, Amsterdam J, Apter J, Londborg P, Tamura R, Tepner RG (2000). Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebocontrolled trial. Br J Psychiatry 176, 363-8.
127. Michelson D, Lydiard RB, Pollack MH, Tamura RN, Hoog SL, Tepner R, Demitrack MA, Tollefson GD (1998). Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group. Am J Psychiatry 155, 1570-7.
128. Michelson D, Pollack M, Lydiard RB, Tamura R, Tepner R, Tollefson G (1999). Continuing treatment of panic disorder after acute response: randomised, placebo-controlled trial with fluoxetine. The Fluoxetine Panic Disorder Study Group. Br J Psychiatry 174, 213-8.
129. Mitte K (2005). A meta-analysis of the efficacy of psycho- and pharmacotherapy in panic disorder with and without agoraphobia. J Affect Disord 88, 27-45.
130. Mochcovitch MD, Nardi AE (2010). Selective serotonin-reuptake inhibitors in the treatment of panic disorder: a systematic review of placebo-controlled studies. Expert Rev Neurother 10, 1285-93.
131. Modigh K, Westberg P, Eriksson E (1992). Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial. J Clin Psychopharmacol 12, 251-61.
132. Mojtabai R, Olfson M, Mechanic D (2002). Perceived need and help-seeking in adults with mood, anxiety, or substance use disorders. Arch Gen Psychiatry 59, 77-84.
133. Montanes-Rada F, de Lucas-Taracena MT, Sanchez-Romero S (2005). Mirtazapine versus paroxetine in panic disorder: an open study. Int J Psych Clin Pract.
134. Monteiro WO, Noshirvani HF, Marks IM, Lelliott PT (1987). Anorgasmia from clomipramine in obsessive-compulsive disorder. A controlled trial. Br J Psychiatry 151, 107-12.
135. Montgomery SA, Prost JF, Solles A, Briley M (1996). Efficacy and tolerability of milnacipran: an overview. Int Clin Psychopharmacol 11 Suppl 4, 47-51.
136. Morilak DA, Frazer A (2004). Antidepressants and brain monoaminergic systems: a dimensional approach to understanding their behavioural effects in depression and anxiety disorders. Int J Neuropsychopharmacol 7, 193-218.
137. Muller WE (2008). Mechanisms of action of the tri- and tetracyclic antidepressives. Adaptive change and reordering of transmitter systems. Pharm Unserer Zeit 37, 198-204.
138. Muth EA, Haskins JT, Moyer JA, Husbands GE, Nielsen ST, Sigg EB (1986). Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol 35, 4493-7.
139. Nardi AE, Freire RC, Mochcovitch MD, Amrein R, Levitan MN, King AL, Valenca AM, Veras AB, Paes F, Sardinha A, Nascimento I, de-Melo-Neto VL, Dias GP, AC ES, Soares-Filho GL, da Costa RT, Mezzasalma MA, de Carvalho MR, de Cerqueira AC, Hallak JE, Crippa JA, Versiani M (2012). A randomized, naturalistic, parallel-group study for the long-term treatment of panic disorder with clonazepam or paroxetine. J Clin Psychopharmacol 32, 120-6.
140. Narita N, Hashimoto K, Tomitaka S, Minabe Y (1996). Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur J Pharmacol 307, 117-9.
141. Noyes R, Jr., Clancy J, Woodman C, Holt CS, Suelzer M, Christiansen J, Anderson DJ (1993). Environmental factors related to the outcome of panic disorder. A seven-year follow-up study. J Nerv Ment Dis 181, 529-38.
142. Oehrberg S, Christiansen PE, Behnke K, Borup AL, Severin B, Soegaard J, Calberg H, Judge R, Ohrstrom JK, Manniche PM (1995). Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study. Br J Psychiatry 167, 374-9.
143. Olfson M, Fireman B, Weissman MM, Leon AC, Sheehan DV, Kathol RG, Hoven C, Farber L (1997). Mental disorders and disability among patients in a primary care group practice. Am J Psychiatry 154, 1734-40.
144. Olfson M, Shea S, Feder A, Fuentes M, Nomura Y, Gameroff M, Weissman MM (2000). Prevalence of anxiety, depression, and substance use disorders in an urban general medicine practice. Arch Fam Med 9, 876-83.
145. Ormel J, Koeter MW, van den Brink W, van de Willige G (1991). Recognition, management, and course of anxiety and depression in general practice. Arch Gen Psychiatry 48, 700-6.
146. Otto MW, Tuby KS, Gould RA, McLean RY, Pollack MH (2001). An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. Am J Psychiatry 158, 1989-92.
147. Owens MJ, Knight DL, Nemeroff CB (2001). Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 50, 345-50.
148. Owens MJ, Krulewicz S, Simon JS, Sheehan DV, Thase ME, Carpenter DJ, Plott SJ, Nemeroff CB (2008). Estimates of serotonin and norepinephrine transporter inhibition in depressed patients treated with paroxetine or venlafaxine. Neuropsychopharmacology 33, 3201-12.
149. Owens MJ, Morgan WN, Plott SJ, Nemeroff CB (1997). Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 283, 1305-22.
150. Owens MJ, Nemeroff CB (1994). Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem 40, 288-95.
151. Pae CU, Serretti A, Patkar AA, Masand PS (2008). Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence. CNS Drugs 22, 367-88.
152. Pande AC, Pollack MH, Crockatt J, Greiner M, Chouinard G, Lydiard RB, Taylor CB, Dager SR, Shiovitz T (2000). Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 20, 467-71.
153. Papp LA (2006). Safety and efficacy of levetiracetam for patients with panic disorder: results of an open-label, fixed-flexible dose study. J Clin Psychiatry 67, 1573-6.
154. Perna G, Bertani A, Caldirola D, Smeraldi E, Bellodi L (2001). A comparison of citalopram and paroxetine in the treatment of panic disorder: a randomized, single-blind study. Pharmacopsychiatry 34, 85-90.
155. Perna G, Favaron E, Di Bella D, Bussi R, Bellodi L (2005). Antipanic efficacy of paroxetine and polymorphism within the promoter of the serotonin transporter gene. Neuropsychopharmacology 30, 2230-5.
156. Perugi G, Frare F, Toni C (2007). Diagnosis and treatment of agoraphobia with panic disorder. CNS Drugs 21, 741-64.
157. Perugi G, Frare F, Toni C, Tusini G, Vannucchi G, Akiskal HS (2010). Adjunctive valproate in panic disorder patients with comorbid bipolar disorder or otherwise resistant to standard antidepressants: a 3-year "open" follow-up study. Eur Arch Psychiatry Clin Neurosci 260, 553-60.
158. Pohl RB, Wolkow RM, Clary CM (1998). Sertraline in the treatment of panic disorder: a double-blind multicenter trial. Am J Psychiatry 155, 1189-95.
159. Pollack MH, Lepola U, Koponen H, Simon NM, Worthington JJ, Emilien G, Tzanis E, Salinas E, Whitaker T, Gao B (2007a). A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depress Anxiety 24, 1-14.
160. Pollack M, Mangano R, Entsuah R, Tzanis E, Simon NM, Zhang Y (2007b). A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. Psychopharmacology (Berl) 194, 233-42.
161. Pollack MH, Otto MW, Worthington JJ, Manfro GG, Wolkow R (1998). Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial. Arch Gen Psychiatry 55, 1010-6.
162. Pollack MH, Rapaport MH, Fayyad R, Otto MW, Nierenberg AA, Clary CM (2002). Early improvement predicts endpoint remission status in sertraline and placebo treatments of panic disorder. J Psychiatr Res 36, 229-36.
163. Pollack MH, Simon NM, Worthington JJ, Doyle AL, Peters P, Toshkov F, Otto MW (2003). Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. J Psychopharmacol 17, 276-82.
164. Pollack MH, Worthington JJ, 3rd, Otto MW, Maki KM, Smoller JW, Manfro GG, Rudolph R, Rosenbaum JF (1996). Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. Psychopharmacol Bull 32, 667-70.
165. Power BM, Hackett LP, Dusci LJ, Ilett KF (1995). Antidepressant toxicity and the need for identification and concentration monitoring in overdose. Clin Pharmacokinet 29, 154-71.
166. Preskorn SH (2004). Milnacipran: a dual norepinephrine and serotonin reuptake pump inhibitor. J Psychiatr Pract 10, 119-26.
167. Primeau F, Fontaine R, Beauclair L (1990). Valproic acid and panic disorder. Can J Psychiatry 35, 248-50.
168. Rampello L, Alvano A, Raffaele R, Malaguarnera M, Vecchio I (2006). New possibilities of treatment for panic attacks in elderly patients: escitalopram versus citalopram. J Clin Psychopharmacol 26, 67-70.
169. Ravindran LN, Stein MB (2010). The pharmacologic treatment of anxiety disorders: a review of progress. J Clin Psychiatry 71, 839-54.
170. Reich J (2003). The effect of Axis II disorders on the outcome of treatment of anxiety and unipolar depressive disorders: a review. J Personal Disord 17, 387-405.
171. Ressler KJ, Nemeroff CB (2000). Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety 12 Suppl 1, 2-19.
172. Ribeiro L, Busnello JV, Kauer-Sant'Anna M, Madruga M, Quevedo J, Busnello EA, Kapczinski F (2001). Mirtazapine versus fluoxetine in the treatment of panic disorder. Braz J Med Biol Res 34, 1303-7.
173. Riddle MA, Reeve EA, Yaryura-Tobias JA, Yang HM, Claghorn JL, Gaffney G, Greist JH, Holland D, McConville BJ, Pigott T, Walkup JT (2001). Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial. J Am Acad Child Adolesc Psychiatry 40, 222-9.
174. Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB (1998). Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 44, 77-87.
175. Roy-Byrne P, Sherbourne C, Miranda J, Stein M, Craske M, Golinelli D, Sullivan G (2006). Poverty and response to treatment among panic disorder patients in primary care. Am J Psychiatry 163, 1419-25.
176. Roy-Byrne PP, Craske MG, Stein MB, Sullivan G, Bystritsky A, Katon W, Golinelli D, Sherbourne CD (2005a). A randomized effectiveness trial of cognitive-behavioral therapy and medication for primary care panic disorder. Arch Gen Psychiatry 62, 290-8.
177. Roy-Byrne PP, Geraci M, Uhde TW (1986). Life events and the onset of panic disorder. Am J Psychiatry 143, 1424-7.
178. Roy-Byrne PP, Russo J, Cowley DS, Katon WJ (2003). Unemployment and emergency room visits predict poor treatment outcome in primary care panic disorder. J Clin Psychiatry 64, 383-9.
179. Roy-Byrne PP, Stang P, Wittchen HU, Ustun B, Walters EE, Kessler RC (2000). Lifetime panic-depression comorbidity in the National Comorbidity Survey. Association with symptoms, impairment, course and help-seeking. Br J Psychiatry 176, 229-35.
180. Roy-Byrne PP, Stein MB, Russo J, Mercier E, Thomas R, McQuaid J, Katon WJ, Craske MG, Bystritsky A, Sherbourne CD (1999). Panic disorder in the primary care setting: comorbidity, disability, service utilization, and treatment. J Clin Psychiatry 60, 492-9; quiz 500.
181. Roy-Byrne PP, Wagner AW, Schraufnagel TJ (2005b). Understanding and treating panic disorder in the primary care setting. J Clin Psychiatry 66 Suppl 4, 16-22.
182. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines team for panic disorder and agoraphobia (2003). Australian and New Zealand clinical practice guidelines for the treatment of panic disorder and agoraphobia. Aust N Z J Psychiatry 37, 641-56.
183. San L, Arranz B (2006). Mirtazapine: only for depression? Acta neuropsychiatrica 18, 130-143.
184. Sarchiapone M, Amore M, De Risio S, Carli V, Faia V, Poterzio F, Balista C, Camardese G, Ferrari G (2003). Mirtazapine in the treatment of panic disorder: an open-label trial. Int Clin Psychopharmacol 18, 35-8.
185. Sareen J, Cox BJ, Afifi TO, de Graaf R, Asmundson GJ, ten Have M, Stein MB (2005). Anxiety disorders and risk for suicidal ideation and suicide attempts: a population-based longitudinal study of adults. Arch Gen Psychiatry 62, 1249-57.
186. Schatzberg AF (2000). Clinical efficacy of reboxetine in major depression. J Clin Psychiatry 61 Suppl 10, 31-8.
187. Schatzberg AF (2003). Efficacy and tolerability of duloxetine, a novel dual reuptake inhibitor, in the treatment of major depressive disorder. J Clin Psychiatry 64 Suppl 13, 30-7.
188. Seedat S, van Rheede van Oudtshoorn E, Muller JE, Mohr N, Stein DJ (2003). Reboxetine and citalopram in panic disorder: a single-blind, cross-over, flexible-dose pilot study. Int Clin Psychopharmacol 18, 279-84.
189. Sepede G, De Berardis D, Gambi F, Campanella D, La Rovere R, D'Amico M, Cicconetti A, Penna L, Peca S, Carano A, Mancini E, Salerno RM, Ferro FM (2006). Olanzapine augmentation in treatment-resistant panic disorder: a 12-week, fixed-dose, open-label trial. J Clin Psychopharmacol 26, 45-9.
190. Serretti A, Artioli P, Quartesan R (2005). Pharmacogenetics in the treatment of depression: pharmacodynamic studies. Pharmacogenet Genomics 15, 61-7.
191. Serretti A, Calati R, Oasi O, De Ronchi D, Colombo C (2007a). Dissecting the determinants of depressive disorders outcome: an in depth analysis of two clinical cases. Ann Gen Psychiatry 6, 5.
192. Serretti A, Chiesa A (2009). Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol 29, 259-66.
193. Serretti A, Kato M, De Ronchi D, Kinoshita T (2007b). Meta-Analysis of Serotonin Transporter Gene Promoter Polymorphism (5-HTTLPR) association with Selective Serotonin Reuptake Inhibitor Efficacy in Depressed Patients. Molecular Psychiatry 12, 247-257.
194. Serretti A, Zanardi R, Mandelli L, Smeraldi E, Colombo C (2007c). A neural network model for combining clinical predictors of antidepressant response in mood disorders. J Affect Disord 98, 239-45.
195. Sharp DM, Power Kg, Simpson RJ (1996). Fluvoxamine, placebo, and cognitive behavioural therapy used alone and in combination in the treatment of panic disorder and agoraphobia. J Anxiety Disord 10, 219-242.
196. Shear MK, Brown TA, Barlow DH, Money R, Sholomskas DE, Woods SW, Gorman JM, Papp LA (1997). Multicenter collaborative panic disorder severity scale. Am J Psychiatry 154, 1571-5.
197. Sheehan DV, Ballenger J, Jacobsen G (1980). Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. Arch Gen Psychiatry 37, 51-9.
198. Sheehan DV, Davidson J, Manschreck T, Van Wyck Fleet J (1983). Lack of efficacy of a new antidepressant (bupropion) in the treatment of panic disorder with phobias. J Clin Psychopharmacol 3, 28-31.
199. Sheehan DV, Raj AB, Sheehan KH, Soto S (1988). The relative efficacy of buspirone, imipramine and placebo in panic disorder: a preliminary report. Pharmacol Biochem Behav 29, 815-7.
200. Silverstone PH (2004). Qualitative review of SNRIs in anxiety. J Clin Psychiatry 65 Suppl 17, 19-28.
201. Simon NM, Emmanuel N, Ballenger J, Worthington JJ, Kinrys G, Korbly NB, Farach FJ, Pollack MH (2003). Bupropion sustained release for panic disorder. Psychopharmacol Bull 37, 66-72.
202. Simon NM, Hoge EA, Fischmann D, Worthington JJ, Christian KM, Kinrys G, Pollack MH (2006). An open-label trial of risperidone augmentation for refractory anxiety disorders. J Clin Psychiatry 67, 381-5.
203. Simon NM, Kaufman RE, Hoge EA, Worthington JJ, Herlands NN, Owens ME, Pollack MH (2009). Open-label support for duloxetine for the treatment of panic disorder. CNS Neurosci Ther 15, 19-23.
204. Slaap BR, den Boer JA (2001). The prediction of nonresponse to pharmacotherapy in panic disorder: a review. Depress Anxiety 14, 112-22.
205. Slemmer JE, Martin BR, Damaj MI (2000). Bupropion is anicotinic antagonist. J Pharmacol Exp Ther 295, 321-7.
206. Snaith RP, Baugh SJ, Clayden AD, Husain A, Sipple MA (1982). The Clinical Anxiety Scale: an instrument derived from the Hamilton Anxiety Scale. Br J Psychiatry 141, 518-23.
207. Stahl SM, Felker A (2008). Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants. CNS Spectr 13, 855-70.
208. Stahl SM, Gergel I, Li D (2003). Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebocontrolled trial. J Clin Psychiatry 64, 1322-7.
209. Stahl SM, Grady MM, Moret C, Briley M (2005). SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr 10, 732-47.
210. Stein MB, Sherbourne CD, Craske MG, Means-Christensen A, Bystritsky A, Katon W, Sullivan G, Roy-Byrne PP (2004). Quality of care for primary care patients with anxiety disorders. Am J Psychiatry 161, 2230-7.
211. Susman J, Klee B (2005). The Role of High-Potency Benzodiazepines in the Treatment of Panic Disorder. Prim Care Companion J Clin Psychiatry 7, 5-11.
212. Taylor CB, Hayward C, King R, Ehlers A, Margraf J, Maddock R, Clark D, Roth WT, Agras WS (1990). Cardiovascular and symptomatic reduction effects of alprazolam and imipramine in patients with panic disorder: results of a double-blind, placebo-controlled trial. J Clin Psychopharmacol 10, 112-8.
213. Terry P, Katz JL (1997). Dopaminergic mediation of the discriminative stimulus effects of bupropion in rats. Psychopharmacology (Berl) 134, 201-12.
214. Tesar GE, Rosenbaum JF (1993). Recognition and management of panic disorder. Adv Intern Med 38, 123-49.
215. Thomas DR, Nelson DR, Johnson AM (1987). Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology (Berl) 93, 193-200.
216. Tiller JW, Bouwer C, Behnke K (1999). Moclobemide and fluoxetine for panic disorder. International Panic Disorder Study Group. Eur Arch Psychiatry Clin Neurosci 249 Suppl 1, S7-10.
217. Toni C, Perugi G, Frare F, Mata B, Akiskal HS (2004). Spontaneous treatment discontinuation in panic disorder patients treated with antidepressants. Acta Psychiatr Scand 110, 130-7.
218. Toni C, Perugi G, Frare F, Mata B, Vitale B, Mengali F, Recchia M, Serra G, Akiskal HS (2000). A prospective naturalistic study of 326 panic-agoraphobic patients treated with antidepressants. Pharmacopsychiatry 33, 121-31.
219. Uhlenhuth EH, Warner TD, Matuzas W (2002). Interactive model of therapeutic response in panic disorder: moclobemide, a case in point. J Clin Psychopharmacol 22, 275-84.
220. Van Ameringen M, Mancini C, Pipe B, Bennett M (2004). Antiepileptic drugs in the treatment of anxiety disorders: role in therapy. Drugs 64, 2199-220.
221. Vaswani M, Linda FK, Ramesh S (2003). Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry 27, 85-102.
222. Versiani M, Cassano G, Perugi G, Benedetti A, Mastalli L, Nardi A, Savino M (2002). Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and welltolerated treatment for panic disorder. J Clin Psychiatry 63, 31-7.
223. Vickers K, McNally RJ (2004). Panic disorder and suicide attempt in the National Comorbidity Survey. J Abnorm Psychol 113, 582-91.
224. Wade AG, Lepola U, Koponen HJ, Pedersen V, Pedersen T (1997). The effect of citalopram in panic disorder. Br J Psychiatry 170, 549-53.
225. Wagner W, Hauser V, Wong LF (1996). The safety profile of fluvoxamine in elderly patients. Human Psychopharmacology 11, 267-272.
226. Warner CH, Bobo W, Warner C, Reid S, Rachal J (2006). Antidepressant discontinuation syndrome. Am Fam Physician 74, 449-56.
227. Watanabe A, Nakao K, Tokuyama M, Takeda M (2005). Prediction of first episode of panic attack among whitecollar workers. Psychiatry Clin Neurosci 59, 119-26.
228. Weissman MM, Bland RC, Canino GJ, Faravelli C, Greenwald S, Hwu HG, Joyce PR, Karam EG, Lee CK, Lellouch J, Lepine JP, Newman SC, Oakley-Browne MA, Rubio-Stipec M, Wells JE, Wickramaratne PJ, Wittchen HU, Yeh EK (1997). The cross-national epidemiology of panic disorder. Arch Gen Psychiatry 54, 305-9.
229. Werneke U, Northey S, Bhugra D (2006). Antidepressants and sexual dysfunction. Acta Psychiatr Scand 114, 384-97.
230. Wittchen HU, Essau CA, von Zerssen D, Krieg JC, Zaudig M (1992). Lifetime and six-month prevalence of mental disorders in the Munich Follow-Up Study. Eur Arch Psychiatry Clin Neurosci 241, 247-58.
231. Wong DT, Bymaster FP (2002). Dual serotonin and noradrenaline uptake inhibitor class of antidepressants potential for greater efficacy or just hype? Prog Drug Res 58, 169-222.
232. Wong DT, Bymaster FP, Mayle DA, Reid LR, Krushinski JH, Robertson DW (1993). LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacology 8, 23-33.
233. Woo JM, Yoon KS, Choi YH, Oh KS, Lee YS, Yu BH (2004). The association between panic disorder and the L/L genotype of catechol-O-methyltransferase. J Psychiatr Res 38, 365-70.
234. Woo JM, Yoon KS, Yu BH (2002). Catechol O-methyltransferase genetic polymorphism in panic disorder. Am J Psychiatry 159, 1785-7.
235. Woodman CL, Noyes R, Jr. (1994). Panic disorder: treatment with valproate. J Clin Psychiatry 55, 134-6.
236. Worthington JJ, 3rd, Kinrys G, Wygant LE, Pollack MH (2005). Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int Clin Psychopharmacol 20, 9-11.
237. Yevtushenko OO, Oros MM, Reynolds GP (2010). Early response to selective serotonin reuptake inhibitors in panic disorder is associated with a functional 5-HT1A receptor gene polymorphism. J Affect Disord 123, 308-11.
238. Young AS, Klap R, Sherbourne CD, Wells KB (2001). The quality of care for depressive and anxiety disorders in the United States. Arch Gen Psychiatry 58, 55-61.
239. Zajecka J, Tracy KA, Mitchell S (1997). Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review. J Clin Psychiatry 58, 291-7.
240. Zwanzger P, Baghai T, Boerner RJ, Moller HJ, Rupprecht R (2001). Anxiolytic effects of vigabatrin in panic disorder. J Clin Psychopharmacol 21, 539-40.
241. Zwanzger P, Eser D, Nothdurfter C, Baghai TC, Moller HJ, Padberg F, Rupprecht R (2009). Effects of the GABAreuptake inhibitor tiagabine on panic and anxiety in patients with panic disorder. Pharmacopsychiatry 42, 266-9.